Answer
Glecaprevir + pibrentasvir targets multiple steps across hepatitis C virus genotypes: glecaprevir inhibits NS3/4A protease, needed for viral polyprotein cleavage and replication, while pibrentasvir inhibits NS5A, essential for viral RNA replication and virion assembly.
Sources for this answer
- Glecaprevir/Pibrentasvir 100 mg/40 mg film-coated tabletsAbbVie Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 24Document updated
Sources checked